The effects of serum uric acid on expression of APP and BACE1 in rats
10.3936/j.issn.1002-0152.2014.08.007
- VernacularTitle:血尿酸对大鼠阿尔茨海默病生物标记物表达的影响
- Author:
Junxia WANG
;
Qingxin LIU
;
Xinxing XIAO
- Publication Type:Journal Article
- Keywords:
Hyperuricemia;
Amyloid recurosr protein;
Beta-site amyloid precursor protein cleaving enzyme-1
- From:
Chinese Journal of Nervous and Mental Diseases
2014;(8):479-482
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effects of the different serum uric acid levels on expression of Alzheimer’s disease biomarkers (APP and BACE1) in rats. Methods Intraperitoneal injection of oxygen of oxazine acid potassium was used to produce HUA models in rats. H&E staining was used to detect the morphological changes of the hippocampus. Western blot was used to detect the protein levels of APP and BACE1 of the hippocampus. Results Compared with nor-mal control group, the serum uric acid and the protein levels of APP and BACE1 in the hippocampus was obviously in-creased at OAPS treatment group (P<0.01). Compared with low dose OAPS treatment group, the serum uric acid level was significantly increased whereas the protein levels of APP and BACE1 in the hippocampus were significantly decreased at the middle and high dose group (P<0.01). Compared with middle dose group, the serum uric acid level was increased at high dose group (P<0.05) and the expression of APP were decreased in the hippocampus rats but the expression of BACE1 remained unchanged (P>0.05). Conclusion The higher level of serum uric acid may be a protective factor of AD. The higher serum uric acid levels, the lower the risk of AD.
